<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00405925</url>
  </required_header>
  <id_info>
    <org_study_id>LTC-184-010403</org_study_id>
    <nct_id>NCT00405925</nct_id>
  </id_info>
  <brief_title>FREE Study: Efficacy and Toxicity of Trizivir</brief_title>
  <official_title>Free Study: a Randomised, Open Label, Multicentre Strategic Study to Evaluate the Efficacy and Toxicity of an Early Switch From a PI-containing Regimen to Trizivir ® on Guidance of Viral Load in HIV-1 Infected , Antiretroviral naïve Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rijnstate Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rijnstate Hospital</source>
  <brief_summary>
    <textblock>
      Antiretroviral naïve patients with &lt;350 xE6/l CD4 cells and a HIV-viral load of &gt; 30.000
      cop/ml are started on combivir ® and Kaletra ®. When patients have reached an undetectable
      viral load of&lt; 50 cop/ml on two consecutive occasions at least at week 12, but no later than
      week 24, they are randomised in either continuation with Combivir/Kaletra or switch to
      Trizivir ® twice daily one pill during 96 weeks. All patients randomised in the
      combivir/Kaletra arm are eligible to switch to Trizivir at any post randomisation visit when
      they reach predefined switch criteria for elevated levels of fasting glucose or lipids.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective is to compare the antiviral efficacy of an early switch from a boosted
      PI/2NRTI regimen to Trizivir (after undetectability of HIV-RNA has been achieved on 2
      consecutive occasions) with uninterrupted use of the PI/2NRTI regimen for 96 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2003</start_date>
  <completion_date type="Actual">September 2009</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma HIV-RNA &lt; 400 cop/ml at week 96 for the Intent- To-Treat (ITT).</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>HIV-RNA &lt;50 cop at week 96</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HIV-RNA &lt;400 and &lt;50 cop/ml at week 48</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to virological failure</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunological efficacy at week 48 and 96 measured by absolute change from baseline in CD4 cell counts</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of change in CD4 cell count from baseline to &gt;200,</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects experiencing one or more predefined values of fasting glucose and triglycerides, LDL and LDL/HDL ratio</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">207</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>combivir/kaletra</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>All patients started with combivir/Kaletra and were randomized if they reached undetectable viral load (2 times) within 24 weeks into continuation of the same regimen or Trizivir (2 arms)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Trizivir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>patients who reach undetectable HIV-RNA within 24 weeks are randomized to switch to trizivir or continuation of combivir/kaletra</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Trizivir</intervention_name>
    <arm_group_label>Trizivir</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zidovudine,lamivudine,abacavir</intervention_name>
    <description>zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid</description>
    <arm_group_label>combivir/kaletra</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults &gt;18 years of age, confirmed HIV-1 infection, never received antiretrovirals
             before, plasma-HIV-RNA &gt;30.000 cop/ml, CD4 &lt; 350 E6/l.

        Exclusion Criteria:

          -  pregnancy, women using proven barrier methods of contraception, defined uncontrolled
             active AIDS defining complication, being on treatment for diabetes, other serious
             illnesses, expected non-compliance, defined laboratory abnormalities
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clemens Richter, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rijnstate Hospital, Arnhem, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. Mulder</last_name>
    <role>Study Director</role>
    <affiliation>Rijnstate Hospital, Arnhem, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>N. Langebeek</last_name>
    <role>Study Director</role>
    <affiliation>Rijnstate Hospital, Arnhem, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>D. N. Burger</last_name>
    <role>Study Director</role>
    <affiliation>Nijmegen, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. P. Koopmans</last_name>
    <role>Study Director</role>
    <affiliation>Nijmegen, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>C. H. ten Napel</last_name>
    <role>Study Director</role>
    <affiliation>Enschede, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. H. Groeneveld</last_name>
    <role>Study Director</role>
    <affiliation>Isala kliniek, Zwolle, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>H. G. Sprenger</last_name>
    <role>Study Director</role>
    <affiliation>Groningen, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. W. ten Kate</last_name>
    <role>Study Director</role>
    <affiliation>Haarlem, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>M. E. van Kasteren</last_name>
    <role>Study Director</role>
    <affiliation>Tilburg, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>J. D. Le grand</last_name>
    <role>Study Director</role>
    <affiliation>Charleroi, Belgium</affiliation>
  </overall_official>
  <overall_official>
    <last_name>R. Vriesendorp</last_name>
    <role>Study Director</role>
    <affiliation>The Hague, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>B. Bravenboer</last_name>
    <role>Study Director</role>
    <affiliation>Eindhoven, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>I. M. Hoepelman</last_name>
    <role>Study Director</role>
    <affiliation>Utrecht, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>P. van Bentum</last_name>
    <role>Study Director</role>
    <affiliation>Rijnstate Hospital, Arnhem, the Netherlands</affiliation>
  </overall_official>
  <overall_official>
    <last_name>A. Smit-den Baars</last_name>
    <role>Study Director</role>
    <affiliation>Rijnstate Hospital, Arnhem, the Netherlands</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rijnstate Hospital</name>
      <address>
        <city>Arnhem</city>
        <state>Gelderland</state>
        <zip>6800 TA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2006</study_first_posted>
  <last_update_submitted>May 31, 2010</last_update_submitted>
  <last_update_submitted_qc>May 31, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 2, 2010</last_update_posted>
  <keyword>AIDS</keyword>
  <keyword>Treatment Naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Zidovudine</mesh_term>
    <mesh_term>Abacavir</mesh_term>
    <mesh_term>Lamivudine, zidovudine drug combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

